Apellis Pharmaceuticals - APLS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $76.23
  • Forecasted Upside: 11.61 %
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 9 Buy Ratings
  • 1 Strong Buy Ratings
$68.30
▲ +2.89 (4.42%)

This chart shows the closing price for APLS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Apellis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APLS

Analyst Price Target is $76.23
▲ +11.61% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Apellis Pharmaceuticals in the last 3 months. The average price target is $76.23, with a high forecast of $113.00 and a low forecast of $40.00. The average price target represents a 11.61% upside from the last price of $68.30.

This chart shows the closing price for APLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 13 polled investment analysts is to buy stock in Apellis Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/9/2021
  • 1 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/8/2021
  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/6/2021
  • 1 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/4/2022
  • 1 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/4/2022
  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/3/2022
  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/1/2022
  • 1 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/1/2022

Latest Recommendations

  • 1 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/12/2022WedbushBoost TargetNeutral$55.00 ➝ $67.00Low
9/8/2022Stifel NicolausBoost TargetBuy$60.00 ➝ $65.00Low
8/18/2022OppenheimerBoost TargetOutperform$68.00 ➝ $78.00Low
8/9/2022Credit Suisse GroupBoost TargetNeutral$49.00 ➝ $52.00Low
8/9/2022Raymond JamesBoost TargetStrong-Buy$102.00 ➝ $113.00Low
8/9/2022The Goldman Sachs GroupBoost TargetBuy$91.00 ➝ $102.00Low
7/20/2022CitigroupBoost TargetBuy$81.00 ➝ $86.00Low
7/19/2022HC WainwrightInitiated CoverageBuy$75.00Low
6/16/2022Stifel NicolausInitiated CoverageBuyHigh
5/24/2022The Goldman Sachs GroupLower TargetBuy$94.00 ➝ $84.00Medium
5/20/2022Credit Suisse GroupBoost Target$49.00High
5/5/2022Raymond JamesLower Target$114.00 ➝ $102.00High
4/13/2022Roth CapitalDowngradeNeutral ➝ Sell$40.00Low
4/4/2022JPMorgan Chase & Co.Boost TargetOverweight$66.00 ➝ $69.00High
3/17/2022CitigroupReiterated RatingFocus List$81.00High
3/16/2022Robert W. BairdBoost TargetOutperform ➝ Outperform$83.00 ➝ $90.00Medium
3/7/2022The Goldman Sachs GroupLower TargetBuy$102.00 ➝ $86.00High
3/1/2022Raymond JamesBoost TargetStrong-Buy$112.00 ➝ $114.00High
1/11/2022Raymond JamesLower TargetStrong-Buy$116.00 ➝ $112.00High
1/7/2022The Goldman Sachs GroupBoost Target$100.00 ➝ $102.00Low
12/31/2021Needham & Company LLCReiterated RatingBuy$70.00N/A
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$84.00Medium
11/29/2021Roth CapitalReiterated RatingBuy ➝ Neutral$46.00 ➝ $40.00Medium
11/24/2021CitigroupBoost TargetBuy$65.00 ➝ $72.00Medium
11/9/2021WedbushLower TargetNeutral ➝ Neutral$34.00 ➝ $28.00High
11/9/2021Raymond JamesBoost TargetStrong-Buy$102.00 ➝ $116.00High
9/13/2021Robert W. BairdBoost TargetOutperform$75.00 ➝ $80.00High
9/12/2021Raymond JamesUpgradeOutperform ➝ Strong-BuyHigh
9/10/2021Robert W. BairdReiterated RatingBuy$75.00High
9/10/2021BMO Capital MarketsLower TargetOutperform$89.00 ➝ $69.00High
9/10/2021Needham & Company LLCLower TargetBuy$85.00 ➝ $70.00High
9/10/2021Roth CapitalLower TargetBuy$80.00 ➝ $46.00High
9/10/2021OppenheimerLower TargetOutperform$80.00 ➝ $65.00High
9/10/2021Credit Suisse GroupLower TargetNeutral$50.00 ➝ $38.00High
9/10/2021WedbushDowngradeOutperform ➝ Neutral$71.00 ➝ $39.00High
8/19/2021WedbushUpgradeNeutral ➝ OutperformHigh
8/19/2021Jefferies Financial GroupInitiated CoverageBuy$74.00High
8/10/2021Needham & Company LLCReiterated RatingBuy$85.00Medium
8/10/2021Credit Suisse GroupBoost TargetNeutral$44.00 ➝ $50.00High
8/10/2021Raymond JamesLower TargetStrong-Buy$115.00 ➝ $102.00High
7/19/2021Needham & Company LLCInitiated CoverageBuy$85.00Medium
7/12/2021Needham & Company LLCReiterated RatingBuy$85.00Medium
7/8/2021BMO Capital MarketsBoost TargetOutperform$68.00 ➝ $89.00High
7/2/2021JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$91.00 ➝ $101.00Low
7/1/2021CowenBoost TargetOutperform$60.00 ➝ $70.00High
6/28/2021Needham & Company LLCBoost TargetBuy$65.00 ➝ $85.00Medium
5/20/2021UBS GroupInitiated CoverageBuy$82.00Low
5/18/2021BMO Capital MarketsBoost TargetOutperform$64.00 ➝ $68.00High
5/18/2021OppenheimerBoost TargetOutperform ➝ Outperform$64.00 ➝ $67.00Medium
5/17/2021Raymond JamesBoost TargetStrong-Buy$104.00 ➝ $115.00Medium
5/17/2021Roth CapitalBoost TargetBuy$69.00 ➝ $80.00High
4/29/2021Credit Suisse GroupBoost TargetNeutral$37.00 ➝ $39.00High
4/16/2021The Goldman Sachs GroupInitiated CoverageBuy$130.00Medium
2/26/2021Credit Suisse GroupBoost TargetNeutral$35.00 ➝ $37.00High
1/29/2021Credit Suisse GroupBoost TargetNeutral$31.00 ➝ $35.00High
1/8/2021Raymond JamesBoost TargetStrong-Buy$78.00 ➝ $104.00Low
12/15/2020Roth CapitalBoost TargetBuy$50.00 ➝ $73.00Low
12/10/2020CowenBoost TargetOutperform$45.00 ➝ $55.00Medium
12/4/2020JPMorgan Chase & Co.Boost Target$50.00 ➝ $875.00Medium
12/1/2020BMO Capital MarketsBoost TargetOutperform$57.00 ➝ $66.00Low
11/23/2020Smith Barney CitigroupBoost Target$53.00 ➝ $67.00Low
11/19/2020Needham & Company LLCInitiated CoverageBuy$59.00Low
10/9/2020Cantor FitzgeraldReiterated RatingOverweightLow
8/31/2020Stifel NicolausInitiated CoverageBuy$40.00High
7/20/2020Roth CapitalInitiated CoverageBuy$50.00High
6/30/2020CitigroupLower TargetBuy$56.00 ➝ $54.00High
6/16/2020BTIG ResearchInitiated CoverageNeutralHigh
6/12/2020OppenheimerReiterated RatingBuy$62.00High
6/8/2020JPMorgan Chase & Co.Boost TargetOverweight$54.00 ➝ $56.00High
5/28/2020UBS GroupInitiated CoverageAddMedium
4/28/2020Cantor FitzgeraldBoost TargetOverweight$54.00 ➝ $61.00High
3/31/2020Raymond JamesInitiated CoverageStrong-Buy$86.00High
3/31/2020BMO Capital MarketsInitiated CoverageOutperform$54.00High
3/11/2020WedbushUpgradeUnderperform ➝ Neutral$29.00High
3/2/2020Credit Suisse GroupLower TargetNeutral$36.00 ➝ $34.00High
2/28/2020CowenReiterated RatingBuy$40.00High
1/7/2020Cantor FitzgeraldReiterated RatingBuy$54.00High
1/7/2020OppenheimerBoost TargetBuy$52.00 ➝ $62.00High
1/7/2020CitigroupBoost Target$37.00 ➝ $80.00High
1/7/2020CowenReiterated RatingBuy$40.00High
1/7/2020SVB LeerinkInitiated CoverageMarket Perform$30.00High
1/7/2020Robert W. BairdReiterated RatingOutperform ➝ Overweight$45.00 ➝ $70.00High
12/19/2019Bank of AmericaInitiated CoverageBuy$36.00High
11/27/2019WedbushInitiated CoverageUnderperform$23.00N/A
11/25/2019Cantor FitzgeraldReiterated RatingOverweight$50.00 ➝ $54.00Medium
11/21/2019WedbushInitiated CoverageUnderperform$23.00High
11/5/2019Credit Suisse GroupInitiated CoverageNeutral$33.00Medium
10/17/2019Cantor FitzgeraldReiterated RatingOverweightLow
8/1/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$52.00 ➝ $50.00Low
7/31/2019CowenSet TargetBuy$40.00Medium
7/12/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$35.00 ➝ $49.00High
7/9/2019OppenheimerInitiated CoverageOutperform$52.00 ➝ $52.00High
6/16/2019CowenReiterated RatingBuy$40.00High
5/8/2019Cantor FitzgeraldReiterated RatingBuy$52.00Medium
3/28/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$45.00Low
2/28/2019Cantor FitzgeraldSet TargetBuy$57.00High
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$34.00High
1/8/2019B. RileyInitiated CoverageBuy$40.00Low
12/20/2018Cantor FitzgeraldReiterated RatingBuy$53.00High
12/6/2018CitigroupBoost TargetBuy$34.00 ➝ $40.00Medium
12/3/2018Cantor FitzgeraldSet TargetBuy$53.00High
11/14/2018JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$38.00 ➝ $34.00High
11/12/2018Cantor FitzgeraldSet TargetBuy$53.00Low
10/1/2018Cantor FitzgeraldSet TargetBuy$53.00Low
9/13/2018B. RileyBoost TargetBuy$27.00 ➝ $40.00Low
9/4/2018Cantor FitzgeraldSet TargetBuy$53.00High
8/7/2018Cantor FitzgeraldBoost TargetOverweight ➝ Buy$52.00 ➝ $53.00Medium
8/1/2018CowenReiterated RatingBuy$40.00Medium
7/31/2018Cantor FitzgeraldSet TargetBuy$52.00High
7/30/2018B. RileyUpgradeNeutral ➝ Buy$27.00High
7/10/2018CowenInitiated CoverageOutperform$40.00Low
6/27/2018Cantor FitzgeraldReiterated RatingBuy$52.00High
6/7/2018Cantor FitzgeraldSet TargetBuy$52.00Low
5/23/2018Cantor FitzgeraldInitiated CoverageOverweightLow
4/12/2018B. RileyDowngradeBuy ➝ Neutral$27.00High
3/23/2018JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$31.00 ➝ $35.00Low
2/8/2018B. RileyInitiated CoverageBuy ➝ Buy$27.00Low
12/4/2017Evercore ISIInitiated CoverageOutperformHigh
12/4/2017CitigroupInitiated CoverageBuy$23.00High
12/4/2017JPMorgan Chase & Co.Initiated CoverageOverweight$31.00High
(Data available from 10/1/2017 forward)

News Sentiment Rating

0.77 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/5/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/4/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/4/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/3/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/3/2022
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/2/2022
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/1/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/1/2022

Current Sentiment

  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Apellis Pharmaceuticals logo
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $68.30
Low: $64.99
High: $69.89

50 Day Range

MA: $62.48
Low: $54.34
High: $68.67

52 Week Range

Now: $68.30
Low: $30.17
High: $70.00

Volume

2,085,555 shs

Average Volume

1,159,234 shs

Market Capitalization

$7.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Apellis Pharmaceuticals?

The following Wall Street research analysts have issued research reports on Apellis Pharmaceuticals in the last year: Citigroup Inc., Credit Suisse Group AG, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Oppenheimer Holdings Inc., Raymond James, Robert W. Baird, Roth Capital, Stifel Nicolaus, The Goldman Sachs Group, Inc., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for APLS.

What is the current price target for Apellis Pharmaceuticals?

13 Wall Street analysts have set twelve-month price targets for Apellis Pharmaceuticals in the last year. Their average twelve-month price target is $76.23, suggesting a possible upside of 11.6%. Raymond James has the highest price target set, predicting APLS will reach $113.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $40.00 for Apellis Pharmaceuticals in the next year.
View the latest price targets for APLS.

What is the current consensus analyst rating for Apellis Pharmaceuticals?

Apellis Pharmaceuticals currently has 1 sell rating, 2 hold ratings, 9 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APLS will outperform the market and that investors should add to their positions of Apellis Pharmaceuticals.
View the latest ratings for APLS.

What other companies compete with Apellis Pharmaceuticals?

How do I contact Apellis Pharmaceuticals' investor relations team?

Apellis Pharmaceuticals' physical mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The company's listed phone number is (617) 977-5700 and its investor relations email address is [email protected] The official website for Apellis Pharmaceuticals is www.apellis.com. Learn More about contacing Apellis Pharmaceuticals investor relations.